WO2020109806A1 - Use of cannabinoids in the treatment of epilepsy - Google Patents

Use of cannabinoids in the treatment of epilepsy Download PDF

Info

Publication number
WO2020109806A1
WO2020109806A1 PCT/GB2019/053372 GB2019053372W WO2020109806A1 WO 2020109806 A1 WO2020109806 A1 WO 2020109806A1 GB 2019053372 W GB2019053372 W GB 2019053372W WO 2020109806 A1 WO2020109806 A1 WO 2020109806A1
Authority
WO
WIPO (PCT)
Prior art keywords
cbd
epilepsy
treatment
seizures
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2019/053372
Other languages
English (en)
French (fr)
Inventor
Geoffrey Guy
Volker KNAPPERTZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Research Ltd
Original Assignee
GW Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2021006094A priority Critical patent/MX2021006094A/es
Priority to AU2019387553A priority patent/AU2019387553A1/en
Priority to US17/296,076 priority patent/US20220008355A1/en
Priority to CA3121230A priority patent/CA3121230A1/en
Priority to BR112021010405-4A priority patent/BR112021010405A2/pt
Priority to JP2021530989A priority patent/JP2022510292A/ja
Priority to CN201980078911.7A priority patent/CN113164411A/zh
Priority to KR1020217020174A priority patent/KR20210098497A/ko
Priority to EP19816424.6A priority patent/EP3886825A1/en
Application filed by GW Research Ltd filed Critical GW Research Ltd
Publication of WO2020109806A1 publication Critical patent/WO2020109806A1/en
Priority to IL283372A priority patent/IL283372A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the CBD may also be used concomitantly with one or more other anti epileptic drugs (AED).
  • AED anti epileptic drugs
  • the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form.
  • the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated. It may also be used as the sole medication, i.e. as a monotherapy.
  • Epilepsy occurs in approximately 1% of the population worldwide, (Thurman et al., 2011) of which 70% are able to adequately control their symptoms with the available existing anti-epileptic drugs (AED). However, 30% of this patient group, (Eadie et ai, 2012), are unable to obtain seizure freedom using the AED that are available and as such are termed as suffering from intractable or“treatment-resistant epilepsy” (TRE).
  • TRE treatment-resistant epilepsy
  • Intractable or treatment-resistant epilepsy was defined in 2009 by the International League against Epilepsy (I LAE) as“failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom” (Kwan et al., 2009).
  • I LAE International League against Epilepsy
  • Focal (partial) seizures where the seizure originates within networks limited to only one hemisphere, are also split into sub-categories.
  • the seizure is characterized according to one or more features of the seizure, including aura, motor, autonomic and awareness / responsiveness.
  • a seizure begins as a localized seizure and rapidly evolves to be distributed within bilateral networks this seizure is known as a Bilateral convulsive seizure, which is the proposed terminology to replace Secondary Generalized Seizures (generalized seizures that have evolved from focal seizures and no longer remain localized).
  • GRIN2A-related speech disorders and epilepsy can include dysarthria and speech dyspraxia, and both receptive and expressive language delay/regression. In more mildly affected individuals a slight impairment of the intelligibility of conversational speech occurs.
  • Epilepsy features in children with a GRIN2A mutation include seizure onset usually between ages three and six years, focal epilepsy with language and/or global developmental regression, and electroencephalogram (EEG) showing continuous spike-and-wave discharges in sleep or very active centrotemporal discharges.
  • Epilepsy syndromes associated with a GRIN2A mutation include: Landau-Kleffner syndrome (LKS), epileptic encephalopathy with continuous spike-and-wave during sleep (ECSWS), childhood epilepsy with centrotemporal spikes (CECTS), atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant rolandic epilepsy with speech dyspraxia (ADRESD), and infantile-onset epileptic encephalopathy.
  • LLS Landau-Kleffner syndrome
  • ECSWS epileptic encephalopathy with continuous spike-and-wave during sleep
  • CECTS childhood epilepsy with centrotemporal spikes
  • ACECTS atypical childhood epilepsy with centrotemporal spikes
  • ADRESD autosomal dominant rolandic epilepsy with speech dyspraxia
  • the CBD is present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD.
  • the extract comprises up to 0.1 % THC. More preferably the extract comprises between 0.2 and 0.1 % (w/w). More preferably the extract further comprises up to 1.0% (w/w) CBDV.
  • the dose of CBD is greater than 5 mg/kg/day.
  • a dose of greater than 75mg of CBD per day would be provided.
  • Doses greater than 5mg/kg/day such as greater than 10/mg/kg/day, greater than 15 mg/kg/day, greater than 20mg/kg/day and greater than 25 mg/kg/day are also envisaged to be effective.
  • the subject is a human, more preferably a child or young adult.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/GB2019/053372 2018-11-30 2019-11-28 Use of cannabinoids in the treatment of epilepsy Ceased WO2020109806A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020217020174A KR20210098497A (ko) 2018-11-30 2019-11-28 뇌전증의 치료에서 카나비노이드의 용도
AU2019387553A AU2019387553A1 (en) 2018-11-30 2019-11-28 Use of cannabinoids in the treatment of epilepsy
US17/296,076 US20220008355A1 (en) 2018-11-30 2019-11-28 Use of cannabinolids in the treatment of epilepsy
CA3121230A CA3121230A1 (en) 2018-11-30 2019-11-28 Use of cannabinoids in the treatment of epilepsy
BR112021010405-4A BR112021010405A2 (pt) 2018-11-30 2019-11-28 Canabidiol, e, método para tratar epilepsia associada a mutação de grin2a
MX2021006094A MX2021006094A (es) 2018-11-30 2019-11-28 Uso de cannabinoides en el tratamiento de epilepsia.
CN201980078911.7A CN113164411A (zh) 2018-11-30 2019-11-28 大麻素在治疗癫痫中的用途
JP2021530989A JP2022510292A (ja) 2018-11-30 2019-11-28 てんかんの治療におけるカンナビノイドの使用
EP19816424.6A EP3886825A1 (en) 2018-11-30 2019-11-28 Use of cannabinoids in the treatment of epilepsy
IL283372A IL283372A (en) 2018-11-30 2021-05-23 Use of cannabinoids in the treatment of epilepsy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1819573.5 2018-11-30
GB1819573.5A GB2580881A (en) 2018-11-30 2018-11-30 Use of cannabinoids in the treatment of epilepsy

Publications (1)

Publication Number Publication Date
WO2020109806A1 true WO2020109806A1 (en) 2020-06-04

Family

ID=65024803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2019/053372 Ceased WO2020109806A1 (en) 2018-11-30 2019-11-28 Use of cannabinoids in the treatment of epilepsy

Country Status (12)

Country Link
US (1) US20220008355A1 (https=)
EP (1) EP3886825A1 (https=)
JP (1) JP2022510292A (https=)
KR (1) KR20210098497A (https=)
CN (1) CN113164411A (https=)
AU (1) AU2019387553A1 (https=)
BR (1) BR112021010405A2 (https=)
CA (1) CA3121230A1 (https=)
GB (1) GB2580881A (https=)
IL (1) IL283372A (https=)
MX (1) MX2021006094A (https=)
WO (1) WO2020109806A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2597313A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597317A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597320A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597318A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597304A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2581517A (en) * 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712A (en) 2011-01-04 2012-08-08 Gw Pharma Ltd Use of the cannabidiol (CBD) in combination with a standard anti-epileptic drug, for the treatment of epilepsy
US20150359755A1 (en) * 2014-06-17 2015-12-17 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531280A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
WO2019045121A1 (en) * 2017-08-31 2019-03-07 Takeda Pharmaceutical Company Limited TREATMENT OF CNS DISEASES
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712A (en) 2011-01-04 2012-08-08 Gw Pharma Ltd Use of the cannabidiol (CBD) in combination with a standard anti-epileptic drug, for the treatment of epilepsy
US20150359755A1 (en) * 2014-06-17 2015-12-17 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
WO2015193667A1 (en) 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531280A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
WO2019045121A1 (en) * 2017-08-31 2019-03-07 Takeda Pharmaceutical Company Limited TREATMENT OF CNS DISEASES
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
ADDIS L. ET AL: "Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue", SCIENTIFIC REPORTS, vol. 7, no. 1, 27 February 2017 (2017-02-27), XP055559141, DOI: 10.1038/s41598-017-00115-w *
AGUILAR-CASTILLO M J ET AL: "Epileptic encephalopathy with phenotype pseudo-Dravet and missense mutation in the GRIN2A gene", CLINICA CHIMICA ACTA, vol. 493, 1 June 2019 (2019-06-01), AMSTERDAM, NL, pages S604 - S618, XP055661121, ISSN: 0009-8981, DOI: 10.1016/j.cca.2019.03.1265 *
AMES FRCRIDLAND S: "Anticonvulsant effects of cannabidiol", S AFR MED J, vol. 69, 1986, pages 14
CONSROE PBENEDICTO MALEITE JRCARLINI EAMECHOULAM R: "Effects of cannabidiol on behavioural seizures caused by convulsant drugs or current in mice", EUR J PHARMACO, vol. 83, 1982, pages 293 - 8
CONSROE PMARTIN PEISENSTEIN D: "Anticonvulsant drug antagonism of delta-9-tetrahydrocannabinol induced seizures in rabbits", RES COMMUN CHEM PATHOL PHARMACOL, vol. 16, 1977, pages 1 - 13
CUNHA JMCARLINI EAPEREIRA AERAMOS OLPIMENTAL CGAGLIARDI R ET AL.: "Chronic administration of cannabidiol to healthy volunteers and epileptic patient", PHARMACOLOGY, vol. 21, 1980, pages 175 - 85, XP009139434, DOI: 10.1159/000137430
DEVINSKY O. ET AL: "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 376, no. 21, 25 May 2017 (2017-05-25), US, pages 2011 - 2020, XP055581640, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1611618 *
DRAVET C.: "The core Dravet syndrome phenotype", EPILEPSIA, vol. 52, no. 2, April 2011 (2011-04-01), pages 3 - 9
EADIE, MJ: "Shortcomings in the current treatment of epilepsy", EXPERT REVIEW OF NEUROTHERAPEUTICS, vol. 12, no. 12, December 2012 (2012-12-01), pages 1419 - 27
GOLYALA A. ET AL: "Drug development for refractory epilepsy: The past 25 years and beyond", SEIZURE, vol. 44, 6 December 2016 (2016-12-06), pages 147 - 156, XP029901803, ISSN: 1059-1311, DOI: 10.1016/J.SEIZURE.2016.11.022 *
HAUSMAN-KEDEM M. ET AL: "Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study", BRAIN AND DEVELOPMENT, vol. 40, no. 7, 1 August 2018 (2018-08-01), NL, pages 544 - 551, XP055660691, ISSN: 0387-7604, DOI: 10.1016/j.braindev.2018.03.013 *
KWAN PARZIMANOGLOU ABERG ATBRODIE MJHAUSER WAMATHERN GMOSHE SLPERUCCA EWIEBE SFRENCH J: "Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies", EPILEPSIA, 2009
MAO K. ET AL: "High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect", INT J CLIN EXP MED, vol. 8, no. 6, 15 June 2015 (2015-06-15), pages 8820 - 8827, XP055660655 *
MECHOULAM RCARLINI EA: "Toward drugs derived from cannabis", DIE NATURWISSENSCHAFTEN, vol. 65, 1978, pages 174 - 9
PERUCCA P. ET AL: "Identifying mutations in epilepsy genes: Impact on treatment selection", EPILEPSY RESEARCH., vol. 152, 4 March 2019 (2019-03-04), NL, pages 18 - 30, XP055660798, ISSN: 0920-1211, DOI: 10.1016/j.eplepsyres.2019.03.001 *
PORTER B. E. ET AL: "Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy", EPILEPSY AND BEHAVIOR, vol. 29, no. 3, 1 December 2013 (2013-12-01), pages 574 - 577, XP028775189, ISSN: 1525-5050, [retrieved on 20131115], DOI: 10.1016/J.YEBEH.2013.08.037 *
PORTER BEJACOBSON C: "Report of a parent survey of cannabidiol-enriched cannabis use in paediatric treatment resistant epilepsy", EPILEPSY BEHAVIOUR, vol. 29, no. 3, December 2013 (2013-12-01), pages 574 - 7, XP028775189, DOI: 10.1016/j.yebeh.2013.08.037
PRESS C. A. ET AL: "Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy", EPILEPSY & BEHAVIOR, vol. 45, 3 April 2015 (2015-04-03), pages 49 - 52, XP055205370, ISSN: 1525-5050, DOI: 10.1016/j.yebeh.2015.02.043 *
PRESS CAKNUPP KGCHAPMAN KE: "Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy", EPILEPSY AND BEHAVIOUR, vol. 45, 2015, pages 49 - 52, XP055205370, DOI: 10.1016/j.yebeh.2015.02.043
RODRÍGUEZ-MUÑOZ M. ET AL: "Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor", MOLECULAR BRAIN, vol. 11, no. 1, 51, 17 September 2018 (2018-09-17), pages 1 - 12, XP055660650, DOI: 10.1186/s13041-018-0395-2 *
ROSENBERG E. C. ET AL: "Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol", EPILEPSIA, vol. 58, no. 8, 15 June 2017 (2017-06-15), pages e96 - e100, XP055657251, ISSN: 0013-9580, DOI: 10.1111/epi.13815 *
STOCKINGS E. ET AL: "Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY, vol. 89, no. 7, 6 March 2018 (2018-03-06), GB, pages 741 - 753, XP055657257, ISSN: 0022-3050, DOI: 10.1136/jnnp-2017-317168 *
THURMAN, DJBEGHI, EBEGLEY, CEBERG, ATBUCHHALTER, JRDING, DHESDORFFER, DCHAUSER, WAKAZIS, LKOBAU, R: "Standards for epidemiologic studies and surveillance of epilepsy", EPILEPSIA, vol. 52, no. 7, September 2011 (2011-09-01), pages 2 - 26
VEZYROGLOU K. ET AL: "Targeted Treatment in Childhood Epilepsy Syndromes", CURRENT TREATMENT OPTIONS IN NEUROLOGY, vol. 18, no. 6, 29, 7 May 2016 (2016-05-07), pages 1 - 12, XP035950701, ISSN: 1092-8480, [retrieved on 20160507], DOI: 10.1007/S11940-016-0407-4 *
WEI F. ET AL: "Ion Channel Genes and Epilepsy: Functional Alteration, Pathogenic Potential, and Mechanism of Epilepsy", NEUROSCIENCE BULLETIN, vol. 33, no. 4, 9 May 2017 (2017-05-09), pages 455 - 477, XP036283175, ISSN: 1673-7067, [retrieved on 20170509], DOI: 10.1007/S12264-017-0134-1 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2597313A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597317A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597320A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597318A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597304A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
WO2022017945A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017949A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with chrna4 mutation
WO2022017958A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
WO2022017960A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
WO2022017952A1 (en) 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Also Published As

Publication number Publication date
KR20210098497A (ko) 2021-08-10
MX2021006094A (es) 2021-07-06
US20220008355A1 (en) 2022-01-13
GB2580881A (en) 2020-08-05
GB201819573D0 (en) 2019-01-16
BR112021010405A2 (pt) 2021-08-24
AU2019387553A1 (en) 2021-06-17
CA3121230A1 (en) 2020-06-04
IL283372A (en) 2021-07-29
JP2022510292A (ja) 2022-01-26
CN113164411A (zh) 2021-07-23
EP3886825A1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
US20220008355A1 (en) Use of cannabinolids in the treatment of epilepsy
AU2022209295B2 (en) Use of cannabidiols in the treatment of epilepsy
US20250177321A1 (en) Use of cannabinoids in the treatment of epilepsy
AU2019211224B2 (en) Use of cannabinoids in the treatment of epilepsy
AU2021269374A1 (en) Use of cannabinoids in the treatment of epilepsy
GB2548873A (en) Use of cannabinoids in treatment of epilepsy
AU2015332208A1 (en) Use of cannabidiol in the treatment of Tuberous Sclerosis Complex
AU2015332212A1 (en) Use of cannabinoids in the treatment of epilepsy
Class et al. Patent application title: USE OF CANNABINOLIDS IN THE TREATMENT OF EPILEPSY Inventors: Geoffrey Guy (Cambridge, GB) Geoffrey Guy (Cambridge, GB) Volker Knappertz (Cambridge, GB)
CA2989779C (en) Use of cannabinoids in the treatment of epilepsy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19816424

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3121230

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021530989

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021010405

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019387553

Country of ref document: AU

Date of ref document: 20191128

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20217020174

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019816424

Country of ref document: EP

Effective date: 20210630

ENP Entry into the national phase

Ref document number: 112021010405

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210528

WWW Wipo information: withdrawn in national office

Ref document number: 283372

Country of ref document: IL

WWW Wipo information: withdrawn in national office

Ref document number: 776600

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020217020174

Country of ref document: KR